Earnings
Home›Earnings›Analyst Ratings›Oscar Health, Hinge Health and Insmed highlight moment…
Oscar Health, Hinge Health and Insmed highlight momentum after strong earnings
The firms posted strong earnings and revenue growth in 2026, while analysts pointed to continued upside even as Medicaid and drug pricing remain key risks.
MarketBeat Ratings highlighted Oscar Health, Hinge Health, and Insmed as three healthcare names showing momentum, citing strong earnings and revenue growth in 2026 and analyst expectations for further upside.
The outlet tied the sector's performance partly to continued interest in GLP-1 medications and the role of AI applications in accelerating drug discovery, while also noting that potential mergers and acquisitions could create opportunities as big pharmaceutical companies face a patent cliff.
At the same time, MarketBeat Ratings flagged major unknowns for the group, including the prospect of cuts to Medicaid funding and regulatory pressure on drug pricing, which could affect broader sector outcomes even for companies that have recently performed well.
The analysis also notes Oscar Health has already performed very well this year, and describes the stock as trading at $29.76 as of 11:33 AM Eastern, with a 52-week range of $10.69 to $34.48.